Skip to main content

Advertisement

SpringerLink
Log in

FXR Agonists: From Bench to Bedside, a Guide for Clinicians

  • DDS Mentored Reviews
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Blumberg B, Evans RM. Orphan nuclear receptors–new ligands and new possibilities. Genes Dev. 1998;12:3149–3155.

    Article  CAS  PubMed  Google Scholar 

  2. Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744.

    Article  CAS  PubMed  Google Scholar 

  3. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191.

    Article  CAS  PubMed  Google Scholar 

  4. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225.

    Article  CAS  PubMed  Google Scholar 

  5. Kok T, Hulzebos CV, Wolters H, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem. 2003;278:41930–41937.

    Article  CAS  PubMed  Google Scholar 

  6. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.

    Article  CAS  PubMed  Google Scholar 

  7. Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci. 2007;28:236–243.

    Article  CAS  PubMed  Google Scholar 

  8. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581–1591.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48:1632–1643.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53:1023–1034.

    Article  CAS  PubMed  Google Scholar 

  11. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988–997.

    Article  CAS  PubMed  Google Scholar 

  12. Pellicciari R, Costantino G, Camaioni E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004;47:4559–4569.

    Article  CAS  PubMed  Google Scholar 

  13. Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Vignozzi L, Morelli A, Filippi S, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med. 2011;8:57–77.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006–1011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–11049.

    Article  CAS  PubMed  Google Scholar 

  17. Ma Y, Huang Y, Yan L, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res. 2013;30:1447–1457.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621–1624.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015;61:1066–1079.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38:S38–S53.

    Article  PubMed  Google Scholar 

  21. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497–1512.

    Article  CAS  PubMed  Google Scholar 

  22. Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28:940–946.

    Article  CAS  PubMed  Google Scholar 

  23. Degirolamo C, Modica S, Vacca M, et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology. 2015;61:161–170.

    Article  CAS  PubMed  Google Scholar 

  24. Guo F, Xu Z, Zhang Y, et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget. 2015;6:34606–34616.

    PubMed  PubMed Central  Google Scholar 

  25. He J, Zhao K, Zheng L, et al. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol Cancer. 2015;14:163.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Flatt B, Martin R, Wang TL, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009;52:904–907.

    Article  CAS  PubMed  Google Scholar 

  27. Mencarelli A, Renga B, Distrutti E, et al. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009;296:H272–H281.

    Article  CAS  PubMed  Google Scholar 

  28. Wu W, Zhu B, Peng X, et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014;443:68–73.

    Article  CAS  PubMed  Google Scholar 

  29. Livero FA, Stolf AM, Dreifuss AA, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact. 2014;217:19–27.

    Article  CAS  PubMed  Google Scholar 

  30. Wu W, Liu X, Peng X, et al. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2014;448:50–55.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380–388.

    Article  CAS  PubMed  Google Scholar 

  32. Yao J, et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol. 2014;20:14430–14441.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Pellicciari R, Zhou CS, Ma X, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.

    Article  CAS  PubMed  Google Scholar 

  34. Wu WB, Xu YY, Cheng WW, et al. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta—a study on maternal cholestasis model. Placenta. 2015;36:545–551.

    Article  CAS  PubMed  Google Scholar 

  35. Lian F, Wang Y, Xiao Y, et al. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis. Mol Med Rep. 2015;12:5821–5827.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Mencarelli A, Renga B, Migliorati M, et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol. 2009;183:6657–6666.

    Article  CAS  PubMed  Google Scholar 

  37. Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286–2298.

    Article  CAS  PubMed  Google Scholar 

  38. Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10:1352–1358.

    Article  CAS  PubMed  Google Scholar 

  39. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.

    Article  PubMed  Google Scholar 

  40. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850.

    Article  CAS  PubMed  Google Scholar 

  41. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-82.e1.

    Article  CAS  PubMed  Google Scholar 

  42. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.

    Article  CAS  PubMed  Google Scholar 

  43. Hameed B, Terrault N, Gill R, et al. Separate and combined effects of obeticholic acid and weight loss in nonalcoholic steatohepatitis (NASH). J Hepatol. 2015;62:S271.

    Article  Google Scholar 

  44. Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751-61.e8.

    Article  CAS  PubMed  Google Scholar 

  45. Kowdley KV, Luketic V, Chapman R. An International Study Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid as Monotherapy in PBC. Vol. 54. Berlin: European Association for the Study of the Liver; 2011.

    Google Scholar 

  46. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.

    Article  PubMed  Google Scholar 

  47. Cho SW, An JH, Park H, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013;28:2109–2121.

    Article  CAS  PubMed  Google Scholar 

  48. Pares A, Pencek R, Peters Y, et al. FXR agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis. J Hepatol. 2015;62:S786.

    Article  Google Scholar 

  49. Mookerjee R, Rosselli M, Pieri G, et al. Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2 a study. J Hepatol. 2014;60:S7-S8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NIDDK/Liver Disease Branch, National Institute of Health, 10 Center Drive, CRC Bldg. 10, RM 4-5722, Bethesda, MD, 20892, USA

    Ahmad Samer Alawad

  2. Division of Hepatology, University of Miami Miller School of Medicine, 1500 NW 12th Avenue, Suite 1101, Miami, FL, 33136, USA

    Cynthia Levy

Authors
  1. Ahmad Samer Alawad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cynthia Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia Levy.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alawad, A.S., Levy, C. FXR Agonists: From Bench to Bedside, a Guide for Clinicians. Dig Dis Sci 61, 3395–3404 (2016). https://doi.org/10.1007/s10620-016-4334-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-016-4334-8

Keywords

Search

Navigation